The Cologne nonverbal screening tool for neuropsychiatric syndromes (KINO): Development and Validation of a non-verbal screening tool to detect neuropsychiatric syndromes in neurological and psychiatric disorders

Recruiting

Conditions: G20
Parkinson disease

Registration Number: DRKS00027467

Lead Sponsor: niversitätsklinikum Köln

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 400

Inclusion Criteria

Vision and hearing: Not impaired or adequately corrected (glasses, hearing aid, etc.)

Knowledge of German: Sufficient knowledge, alternatively sufficient knowledge of Turkish

Language: Sufficient language skills (ACL-K=14)

Patients who are in inpatient/outpatient treatment in the Clinic and Polyclinic for Neurology or Clinic and Polyclinic for Psychiatry and Psychotherapy, in Cologne, Germany

Cognitive status: No substantial impairment (DemTect> 8)

Consent and signed

Exclusion Criteria

Vision and hearing impaired, insufficient knowledge of German OR Turkish,
Substantial linguistic impairments (ACL-K <14), patients in whom neurological and psychiatric diseases were definitely excluded; Moderate or severe medical conditions that interfere with the ability to complete the study.

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The aim of the study is to develop and validate a new, multidimensional screening instrument (Cologne instrument for the non-verbal recording of neuropsychiatric syndromes; KINO) for the mainly speech-free recording of depression, anxiety, apathy, fatigue, mania, impulse control disorders and psychosis in neurological and psychiatric patients (including healthy controls). The current version of the screening instrument comprises 31 items (6 items for depression, 5 items for mania, 5 items for impulse control disorders, 4 items for anxiety, 3 items for fatigue, 3 items for apathy, 5 items for psychosis). The assessment time is approximately 10 minutes. Another aim is the validation of a newly developed language-based screening questionnaire (Parkinson's Disease Affective State; PADAS) for the assessment of neuropsychiatric syndromes in patients with Parkinson's disease.

Secondary Outcome Measures